Posted by Michael Wonder on 07 May 2026
Armata Pharmaceuticals secures FDA fast track designation for AP-SA02
7 May 2026 - Armata Pharmaceuticals today announced that the US FDA has granted fast track designation to AP-SA02, the Company's intravenously administered Staphylococcus aureus multi-phage product candidate, for adjunct treatment of complicated bacteraemia caused by methicillin-sensitive S. aureus or methicillin resistant S. aureus.
Armata is developing AP-SA02, a fixed multi-phage cocktail, for the adjunct treatment of complicated Staphylococcus aureus bacteraemia caused by methicillin-sensitive S. aureus or methicillin resistant S. aureus.
